PPP1R14A: A Potential Drug Target and Biomarker for Protein Kinase C Inhibition

Target Name: PPP1R14A

NCBI ID: G94274

PPP1R14A

PPP1R14A: A Potential Drug Target and Biomarker for Protein Kinase C Inhibition

Introduction

Protein kinase C (PKC) is a ubiquitous protein that plays crucial roles in various cellular processes, including cell signaling, DNA replication, and inflammation. Dysregulation of PKC activity has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, the development of selective and potent inhibitors of PKC activity has significant implications for the treatment of these diseases. One of the promising candidates for PKC inhibition is PPP1R14A, a protein kinase C (PKC)-potentiated inhibitor protein with 17 kDa.

PPP1R14A: Structure and Function

PPP1R14A is a 17 kDa protein that is expressed in various tissues, including liver, kidney, and brain. It is a member of the PKC subfamily and is characterized by a N-terminal catalytic domain, a central 尾-sheet, and a C- terminal hypervariable region (HVR). PPP1R14A has been shown to inhibit the activity of PKC with a potency of up to 100 nM.

PPP1R14A's unique feature is its ability to act as a potent inhibitor of PKC activity, even in the presence of high levels of PKC. This is due to the presence of a C-terminal HVR that allows PPP1R14A to interact with and inhibit the activity of PKC.

PPP1R14A's efficacy in inhibiting PKC activity makes it an attractive drug target for the treatment of various diseases associated with PKC dysregulation.

Disease-Relevance

The inhibition of PKC activity by PPP1R14A has the potential to treat a wide range of diseases that are caused by PKC dysregulation. Some of the most relevant diseases that may benefit from PPP1R14A include:

1. Cancer: The deregulation of PKC activity is a well-established hallmark of cancer. The inhibition of PKC activity by PPP1R14A has the potential to generate new treatments for various types of cancer.

2. Neurodegenerative Diseases: PKC is involved in the development and progression of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The inhibition of PKC activity by PPP1R14A may have therapeutic benefits in the treatment of these diseases.

3. Autoimmune Disorders: PKC is involved in the regulation of immune responses, and dysregulation of PKC activity has been implicated in the development of several autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. The inhibition of PKC activity by PPP1R14A may have therapeutic benefits in the treatment of these disorders.

4. Inflammatory Diseases: PKC is involved in the regulation of inflammation and has been implicated in the development of several inflammatory diseases, including arthritis, atherosclerosis, and chronic obstructive pulmonary disease (COPD). The inhibition of PKC activity by PPP1R14A may have therapeutic benefits in the treatment of these diseases.

Conclusion

In conclusion, PPP1R14A is a promising drug target and biomarker for the treatment of various diseases associated with PKC dysregulation. The inhibition of PKC activity by PPP1R14A has the potential to generate new treatments for these diseases, including cancer, neurodegenerative diseases, autoimmune disorders, and inflammatory diseases. Further studies are needed to confirm the efficacy and safety of PPP1R14A as a potential drug.

Protein Name: Protein Phosphatase 1 Regulatory Inhibitor Subunit 14A

Functions: Inhibitor of PPP1CA. Has over 1000-fold higher inhibitory activity when phosphorylated, creating a molecular switch for regulating the phosphorylation status of PPP1CA substrates and smooth muscle contraction

The "PPP1R14A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP1R14A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets